Ridker PM, et al. - In this randomized, double-blind trial, researchers assessed 4786 patients with previous myocardial infarction or multivessel coronary disease, additionally type 2 diabetes/metabolic syndrome to examine if an alternative approach to inflammation inhibition with low-dose methotrexate might provide similar advantages. All participants were given 1 mg of folate daily. They observed no impact of methotrexate in lowering interleukin-1β, interleukin-6, or C-reactive protein levels as compared to placebo among subjects with stable atherosclerosis. They found an association of methotrexate with elevations in liver-enzyme levels, a decline in leukocyte counts and hematocrit levels, and a higher incidence of non–basal-cell skin cancers in comparison to placebo.